Novexel Appoints Chief Financial Officer
News Jan 23, 2006
Novexel has announced the appointment of Gordon Waldron as Chief Financial Officer with immediate effect.
Gordon joins Novexel from the French biotechnology company Synt:em S.A., where he held the position of Vice President Finance & CFO from 1997.
During this time he built a pan-European, blue chip investor base, raised €30 million in private equity financing, negotiated a technology out licensing deal with a US public biotech company and ultimately the sale of Synt:em to a private French pharmaceutical company.
Prior to Synt:em, Gordon was Group Finance Manager for Europe, Africa and Middle East at Texas Instruments Software in the UK, which involved Group Financial and Management Accounting for 17 legal entities and a distributor network across 14 countries.
During this time, Gordon participated in negotiations for various MBO/entity disposal projects.
Gordon also worked for the Paris branch of Texas Instruments Software where he was Finance Director of their start-up subsidiary.
Previously, Gordon held Controller positions at Spie Batignolles in both the US and France.
Iain Buchanan, CEO of Novexel, commented, "I am delighted to welcome Gordon to Novexel in this key role. His breadth of financial experience will be of tremendous value as we continue to build the Company in 2006 and beyond."
Tuberculosis (TB), an ancient and notoriously difficult disease to treat, has killed millions through the course of human history; and the antibiotics that have been used to fight the disease in recent history are becoming less and less effective. In the face of this reality, researcher Prof. Dennis Wright has improved upon a new way to thwart the tricky pathogen, mycobacterium tuberculosis.READ MORE
Researchers have solved the structures of the cancer-promoting enzymes USP25 and USP28, and identified significant differences in their activities. This knowledge provides the molecular basis for the development of new and highly specific anti-cancer drugs, with a low risk of side-effects.READ MORE